Global generic pharma manufacturer with biosimilars and formulation focus
Intas is a $2.5B+ pharmaceutical formulation and manufacturing operation headquartered in India, present in 85+ countries with 70%+ revenue from international markets. The tech stack reveals a Microsoft-centric cloud-native architecture (Azure, .NET, Kubernetes, SAP IBP) optimized for supply-chain visibility and regulatory compliance—matching their stated pain points around data reconciliation, automation resilience, and multi-jurisdictional monitoring. Hiring is finance-weighted (10 roles) and accelerating, suggesting active restructuring around tax planning, transfer pricing, and cost compliance initiatives.
Intas manufactures pharmaceutical formulations, generics, and biosimilars across 17 facilities (10 in India, 7 across UK, Mexico, Greece). The company operates under the Accord Healthcare subsidiary brand in regulated markets (EU, US, Canada, Australia, APAC, MENA, CIS). With 23,000+ employees, 6-7% R&D investment, and over 10,000 product registrations, Intas holds market-leading positions in CNS, cardio, diabetic, gastrointestinal, urology, and oncology segments in India, and ranks top-10 among generic players in EU, US, and UK. Facilities carry USFDA, EMA, MHRA, and TGA accreditations. The company maintains a pipeline of 300+ molecules spanning first-to-file, first-to-market, biosimilars, and novel drug-delivery candidates.
Intas runs SAP IBP and SAP for enterprise resource planning, Python with LangChain and Azure OpenAI for analytics, .NET/ASP.NET Core for applications, and Azure cloud services (App Service, Functions, API Management, Service Bus, SQL Managed Instance, Kubernetes) for infrastructure and DevOps via Azure Pipelines, GitHub Actions, and Azure DevOps.
Intas employs 23,000+ people globally across formulation, R&D, and distribution operations in India, UK, Mexico, and Greece.
Other companies in the same industry, closest in size